Saquinavir and Ritonavir: Arrhythmia Risks

Links shared publicly online about this topic

Saquinavir and ritonavir: Arrhythmia risks

theheart.org — “Preliminary data suggest that the combination of saquinavir and ritonavir may cause prolongation of the QT and PR intervals, leading to an increased risk of torsades de pointes and heart block, respectively.View full resource at theheart.org

  • View Related
  • Share

Most Recently Shared on February 23, 2010 at 8:11 pm By:

theheartorg Shelley Wood Cardiology

FDA warning: HIV drug combo and rhythm disturbances: Preliminary data suggest that the combination of saquinavir a... http://bit.ly/axM79Z

2 years ago...

Symposier - Review of HIV medication Invirase (saquinavir) and Cardiac Arrhythmias

symposier.com — “Uploaded and Shared in Youtube by: USFoodandDrugAdmin FDA is reviewing clinical trial data suggesting that using Invirase (saquinavir) in combination with Norvir (ritonavir) may increase the risk of cardiac arrhythmias. Invirase and Norvir are protease inhibitors used in combination to treat HIV infection. The study was conducted by Roche, the manufacturer of Invirase, in response to FDA's request that all manufacturers of protease inhibitors evaluate the effect of these drugs on QT and PR View full resource at symposier.com

  • View Related
  • Share

Most Recently Shared on May 24, 2010 at 10:17 pm By:

SympoCardiology Symposier Cardiology Cardiology and Health Business

Review of HIV medication Invirase (saquinavir) and Cardiac Arrhythmias. http://bit.ly/9rZAqS

2 years ago...

FDA Alert: Invirase (saquinavir): Label Change - Risk of Abnormal Heart Rhythm

drugs.com — “FDA Alert: Invirase (saquinavir): Label Change - Risk of Abnormal Heart RhythmView full resource at drugs.com

  • View Related
  • Share

Most Recently Shared on October 21, 2010 at 8:52 pm By:

drugscom Drugs.com Health Site

FDA Alert - Labeling Change for Invirase (saquinavir) - Risk of Abnormal Heart Rhythm - http://bit.ly/9nxaPY

2 years ago...

FDA Alert: Invirase (saquinavir): Label Change - Risk of Abnormal Heart Rhythm

drugs.com — “FDA Alert: Invirase (saquinavir): Label Change - Risk of Abnormal Heart RhythmView full resource at drugs.com

  • View Related
  • Share

Most Recently Shared on October 21, 2010 at 9:06 pm By:

Drugs_Devices Drugs and Devices OW OW Health

Invirase (saquinavir): Label Change - Risk of Abnormal Heart Rhythm: Audience: Cardiology, Infectious Disease ... http://bit.ly/at3Bk4 #FDA

2 years ago...

Invirase (saquinavir): Label Change - Risk of Abnormal Heart Rhythm

fda.gov — “Prolonged QT or PR intervals reported when Invirase is used with the antiviral medication, Norvir (ritonavir).View full resource at fda.gov

  • View Related
  • Share

Most Recently Shared on October 21, 2010 at 7:58 pm By:

tdanton Trish D'Antonio Health Professional

Getting the word out: FDA: Invirase (saquinavir): Label Change - Risk of Abnormal Heart Rhythm (http://bit.ly/9sMymg)

2 years ago...

Invirase (saquinavir): Ongoing safety review of clinical trial data

fda.gov — “Possible association with abnormal heart rhythms when used in combination with Norvir (ritonavir).View full resource at fda.gov

  • View Related
  • Share

Most Recently Shared on February 25, 2010 at 11:33 am By:

josephweaver Joe Weaver, RN Nurse

Invirase (saquinavir): Ongoing safety review of clinical trial data http://tinyurl.com/yfde83n

2 years ago...

FDA Alert: Invirase (saquinavir): Ongoing safety review of clinical trial data

drugs.com — “FDA Alert: Invirase (saquinavir): Ongoing safety review of clinical trial dataView full resource at drugs.com

  • View Related
  • Share

Most Recently Shared on February 23, 2010 at 9:30 pm By:

drugscom Drugs.com Health Site

FDA Alert - Invirase (saquinavir): Ongoing safety review of clinical trial data - http://bit.ly/axMLC8

2 years ago...

European Medicines Agency Concludes That Benefit-risk Balance Of Invirase Remains Positive

medicalnewstoday.com — “The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has reviewed all available data on Invirase (saquinavir) and the potential risk of arrhythmia, and concluded tView full resource at medicalnewstoday.com

  • View Related
  • Share

Most Recently Shared on October 25, 2010 at 10:24 am By:

HeartsHealth Heart Health Health News

MedicalNewsToday: European Medicines Agency Concludes That Benefit-risk Balance Of Invirase: http://bit.ly/95ph0o Full http://bit.ly/ctj2iu

2 years ago...

HIV Drug Combination Invirase Plus Norvir Can Cause Life Threatening Heart Problems

medicalnewstoday.com — “HIV antiviral medication Invirase (saquinavir) when taken in combination with Norvir (ritonavir), also an HIV antiviral, can increase the risk of life-threatening heart rhythm abnormalities, triggView full resource at medicalnewstoday.com

  • View Related
  • Share

Most Recently Shared on October 22, 2010 at 9:08 pm By:

HIV_Wisdom OrganizedWisdom HIV OW Health

HIV Drug Combination Invirase Plus Norvir Can Cause Life Threatening Heart Problems: HIV antiviral medication Invi... http://mnt.to/f/3LDP

2 years ago...

Invirase labeling updated to include cardiac risk with Norvir - ONA

oncologynurseadvisor.com — “The FDA announced that new safety information has been added to the label for Invirase (saquinavir, from Genentech), describing potentially life-threatening cardiac effects when used with Norvir (ritonavir, from Abbott).View full resource at oncologynurseadvisor.com

  • View Related
  • Share

Most Recently Shared on October 21, 2010 at 7:21 pm By:

FDA reviews cardiac risk of Invirase in combination with Norvir - ONA

oncologynurseadvisor.com — “The FDA has notified healthcare professionals and patients that it is reviewing clinical trial data about a potentially serious effect on the heart associated with the use of Invirase (saquinavir, from Roche) in combination with Norvir (ritonavir, from Abbott).View full resource at oncologynurseadvisor.com

  • View Related
  • Share

Most Recently Shared on February 23, 2010 at 9:09 pm By:

FDA reviews cardiac risk of Invirase in combination with Norvir - MPR

empr.com — “The FDA has notified healthcare professionals and patients that it is reviewing clinical trial data about a potentially serious effect on the heart associated with the use of Invirase (saquinavir, from Roche) in combination with Norvir (ritonavir, from Abbott).View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on February 23, 2010 at 9:07 pm By:

eMPR MPR Medical Publisher

MPR News: FDA reviews cardiac risk of Invirase in combination with Norvir: The FDA has notified healthcare profess... http://bit.ly/bNJGxD

2 years ago...

Invirase labeling updated to include cardiac risk with Norvir - MPR

empr.com — “The FDA announced that new safety information has been added to the label for Invirase (saquinavir, from Genentech), describing potentially life-threatening cardiac effects when used with Norvir (ritonavir, from Abbott).View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on October 21, 2010 at 9:06 pm By:

eMPR MPR Medical Publisher

MPR News: Invirase labeling updated to include cardiac risk with Norvir: The FDA announced that new safety informa... http://bit.ly/9u5okh

2 years ago...

The Top 3 resources shared on this topic. More resources.

Key stats and trends about this topic

Featuring the top 3 experts for this topic

  • theheartorg

    Shelley Wood

    Managing editor for heartwire on theheart.org--the most authoritative, balanced, and insightful cardiovascular disease news online. http://is.gd/nHJ4

    View Profile

  • SympoCardiology

    Symposier Cardiology

    Symposier.com, the technological platform that will allow you (and your colleagues) to share medical information, and much more with medicine professionals.

    View Profile

  • drugscom

    Drugs.com

    Keeping you up to date with the latest medication news, FDA Medwatch alerts and new drug approvals.

    View Profile

Advertisement

Share via Email

Share this WisdomCard with others by embedding on your site or blog.

300x260

425x300

560x390